Finance

Taking notes at conference
First Opinion

The J.P. Morgan Healthcare Conference has grown. How can we make it work for everyone?

By Dennis Purcell

Breast Cancer Cell
Biotech

New York biotech debuts, targeting dormant metastatic cancer cells

By Sharon Begley

Pharmalot

Pharmalittle: Trump leaves Democrats confused over drug pricing; Vertex dismisses U.K. licensing threat

By Ed Silverman

Biotech

After a stormy winter, biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

By Damian Garde

Pharmalot

Allergan is pressured once again by a big hedge fund to split chairman and CEO jobs

By Ed Silverman

Play
The Readout LOUD

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

By Damian Garde and Rebecca Robbins

Pharmalot

Pharmalittle: Roche halts Alzheimer’s drug trials; is public health jeopardized as FDA fast tracks generics?

By Ed Silverman

Millions of dollars
Biotech

Lyndra Therapeutics raises $55 million from Gilead and Gates

By Kate Sheridan

Elizabeth Warren
First Opinion

The Warren bill could promote beneficial public-private partnerships in life sciences

By Su Linna

Purdue Pharmaceuticals
Health

Tufts to review ties to Purdue Pharma after ‘deeply troubling’ disclosures

By Andrew Joseph

Peter Welch
Pharmalot

Lawmakers want feds to look at how a Bristol-Celgene deal affects prices and competition

By Ed Silverman

Pharmalot

Pharmalittle: ‘Netflix’ model for hep C drugs proceeds; J&J hikes drug prices

By Elizabeth Cooney

Baby biotech goes to JPM
Biotech

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

By Kate Sheridan

China's Kendall Square
Biotech

Chinese biotech was big at JPM. Attendees were enthusiastic — and wary

By Rebecca Robbins

JPM 2019 - Painted Ladies
Go West

Where’s Big Tech at biopharma’s big bash?

By Rebecca Robbins

Pharma TV Ad
Pharmalot

Medical marketing exploded over the past two decades, raising questions about industry influence

By Ed Silverman

Biotech

Sanofi to exit immuno-oncology collaboration with Regeneron

By Kate Sheridan

Pharmalot

Pharmalittle: Lilly makes a huge bet on Loxo; what about the Michaels?

By Elizabeth Cooney and Ed Silverman

JPM 2018
Biotech

A year after ‘the Michaels,’ more women will take the JPM stage — but 90 percent of presenters are still male

By Rebecca Robbins

STAT SPOTLIGHT
Health

Startup Spotlight: Vedanta Biosciences eyes large-scale clinical trials for microbiome drugs

By Kate Sheridan

Mike Huckman headshot
Biotech

What not to say at J.P. Morgan, according to a conference veteran

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

JPM 2019 - Painted Ladies
Biotech

The pull of JPM may be irresistible, but will San Francisco’s problems push people away?

By Adam Feuerstein, Rebecca Robbins, and Damian Garde

Biotech

9 big takeaways from the $74 billion Bristol-Celgene deal

By Damian Garde, Adam Feuerstein, and Ed Silverman

Pharmalot

Pharmalittle: Bristol-Myers to pay $74 billion for Celgene; Trump expects drug prices to fall

By Ed Silverman

Celgene
Biotech

Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal

By Adam Feuerstein and Matthew Herper

Microscope
First Opinion

A dearth of physician innovators can derail new biomedical startups

By Vijay Pande and James L. Madara

Biotech graveyard
Biotech

Crash and burn: Why three biotechs failed in 2018

By Kate Sheridan

Stealth bomber
Biotech

New details emerge about a stealth startup backed by Flagship Pioneering

By Kate Sheridan

A dosage of Spinraza.
Pharmalot

Two high-priced drugs for spinal muscular atrophy are not cost effective, analysis concludes

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy